|
ES2683352T3
(es)
|
2009-04-13 |
2018-09-26 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Partículas de HPV y usos de las mismas
|
|
US9511092B2
(en)
|
2013-01-28 |
2016-12-06 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
|
|
EP3517130B1
(en)
|
2013-09-18 |
2022-03-30 |
Aura Biosciences, Inc. |
Method of producing photosensitive molecules
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
DK3071222T3
(da)
|
2013-11-21 |
2020-11-16 |
Ucl Business Ltd |
Celle
|
|
US10676528B2
(en)
*
|
2013-12-06 |
2020-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
|
MX386422B
(es)
|
2013-12-20 |
2025-03-18 |
Fred Hutchinson Cancer Center |
Moléculas efectoras químericas etiquetadas y receptores de las mismas.
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
US10611837B2
(en)
|
2014-04-10 |
2020-04-07 |
Seattle Children's Hospital |
Transgene genetic tags and methods of use
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
WO2016097231A2
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
|
CN114107212A
(zh)
*
|
2014-12-24 |
2022-03-01 |
奥托路斯有限公司 |
细胞
|
|
AU2016212158B2
(en)
|
2015-01-26 |
2021-06-03 |
Allogene Therapeutics, Inc. |
mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
|
|
EP3250611B1
(en)
*
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
JP6895380B2
(ja)
|
2015-02-06 |
2021-06-30 |
ナショナル ユニバーシティ オブ シンガポール |
治療免疫細胞の有効性を改良するための方法
|
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
HRP20220893T1
(hr)
*
|
2015-04-08 |
2022-10-14 |
Novartis Ag |
Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
US11827904B2
(en)
*
|
2015-04-29 |
2023-11-28 |
Fred Hutchinson Cancer Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
AU2016265845B2
(en)
*
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
AU2016271147B2
(en)
*
|
2015-05-29 |
2022-09-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
EP4424326A3
(en)
|
2015-06-10 |
2024-11-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
US11458167B2
(en)
*
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
GB201514874D0
(en)
*
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
JP2018532801A
(ja)
|
2015-10-30 |
2018-11-08 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
標的化がん療法
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
AU2017225733A1
(en)
*
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
US11400116B2
(en)
|
2016-05-06 |
2022-08-02 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
EP3458077A4
(en)
*
|
2016-05-17 |
2020-04-01 |
Chimera Bioengineering Inc. |
METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
|
|
JP7114490B2
(ja)
*
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
|
CN107893052B
(zh)
*
|
2016-09-09 |
2023-11-03 |
科济生物医药（上海）有限公司 |
融合蛋白及其应用
|
|
US11219646B2
(en)
*
|
2016-09-30 |
2022-01-11 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
US20190352409A1
(en)
|
2016-11-11 |
2019-11-21 |
Autolus Limited |
Chimeric antigen receptor
|
|
US11440958B2
(en)
|
2016-11-22 |
2022-09-13 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
CA3045665A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
JP7382829B2
(ja)
|
2017-01-10 |
2023-11-17 |
ザ ジェネラル ホスピタル コーポレイション |
キメラ抗原受容体を発現するｔ細胞
|
|
JP2020506700A
(ja)
*
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
JP7356354B2
(ja)
*
|
2017-05-12 |
2023-10-04 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
JP7132249B2
(ja)
*
|
2017-05-15 |
2022-09-06 |
オートラス リミテッド |
キメラ抗原受容体（ｃａｒ）を含む細胞
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
EP3662055A1
(en)
*
|
2017-08-02 |
2020-06-10 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
JP2020530291A
(ja)
|
2017-08-10 |
2020-10-22 |
ナショナル ユニバーシティ オブ シンガポール |
Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
|
|
CA3077174A1
(en)
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
A universal platform for preparing an inhibitory chimeric antigen receptor (icar)
|
|
US11905528B2
(en)
*
|
2017-10-12 |
2024-02-20 |
Icell Gene Therapeutics Inc. |
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
|
|
CN111132701A
(zh)
|
2017-10-25 |
2020-05-08 |
锕医药股份有限公司 |
基于抗-cd45的调理方法及其与基于基因编辑细胞的疗法的联合应用
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
WO2019090003A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
WO2019177986A1
(en)
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
|
CN112119096B
(zh)
|
2018-05-15 |
2024-04-30 |
奥托路斯有限公司 |
嵌合抗原受体
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
KR20210008408A
(ko)
|
2018-05-23 |
2021-01-21 |
싱가포르국립대학교 |
T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
JP7560882B2
(ja)
|
2018-08-29 |
2024-10-03 |
ナショナル ユニヴァーシティー オブ シンガポール |
遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
|
|
HUE069503T2
(hu)
|
2018-09-27 |
2025-03-28 |
Autolus Ltd |
Kiméra antigénreceptor
|
|
CA3109747A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3860642A1
(en)
*
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
CN113412117B
(zh)
|
2018-12-12 |
2025-03-04 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
US20220133791A1
(en)
|
2019-01-23 |
2022-05-05 |
Miltenyi Biotec B.V. & Co. KG |
A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
WO2020183131A1
(en)
|
2019-03-08 |
2020-09-17 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
AU2020265679A1
(en)
|
2019-04-30 |
2021-12-23 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
SG11202111532SA
(en)
|
2019-05-01 |
2021-11-29 |
Pact Pharma Inc |
Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy
|
|
CA3140064A1
(en)
*
|
2019-05-16 |
2020-11-19 |
University Of Washington |
Lockr-mediated recruitment of car t cells
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
WO2021009510A1
(en)
|
2019-07-16 |
2021-01-21 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
CN114585371A
(zh)
*
|
2019-08-20 |
2022-06-03 |
森迪生物科学公司 |
嵌合抑制性受体
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
WO2021055372A1
(en)
*
|
2019-09-16 |
2021-03-25 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
|
CN114929752A
(zh)
*
|
2019-10-08 |
2022-08-19 |
省卫生服务机构 |
嵌合细胞因子受体
|
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
|
US20220411535A1
(en)
*
|
2019-11-26 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
IL293716A
(en)
|
2019-12-11 |
2022-08-01 |
A2 Biotherapeutics Inc |
Lilrb1-based chimeric antigen receptor
|
|
WO2021156277A1
(en)
|
2020-02-04 |
2021-08-12 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
WO2021168298A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Senti Biosciences, Inc. |
Inhibitory chimeric receptor architectures
|
|
CN115397845A
(zh)
*
|
2020-02-20 |
2022-11-25 |
森迪生物科学公司 |
抑制性嵌合受体架构
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
EP3915578A1
(en)
|
2020-05-28 |
2021-12-01 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising c2-set ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
US20230310606A1
(en)
|
2020-07-17 |
2023-10-05 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
JP7621461B2
(ja)
|
2020-08-20 |
2025-01-24 |
エー２ バイオセラピューティクス， インコーポレイテッド |
Ｅｇｆｒ陽性がんを治療するための組成物及び方法
|
|
MX2023002017A
(es)
|
2020-08-20 |
2023-04-28 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para ceacam.
|
|
IL300500A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of mesothelin positive cancer
|
|
US11976297B2
(en)
*
|
2020-09-21 |
2024-05-07 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with receptor cross-talk
|
|
WO2022081975A1
(en)
*
|
2020-10-15 |
2022-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibition of natural killer cell receptors
|
|
US20230405047A1
(en)
|
2020-11-09 |
2023-12-21 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11883432B2
(en)
|
2020-12-18 |
2024-01-30 |
Century Therapeutics, Inc. |
Chimeric antigen receptor system with adaptable receptor specificity
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
AU2022221606A1
(en)
|
2021-02-16 |
2023-08-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
WO2022251377A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
|
|
US20240336903A1
(en)
*
|
2021-08-19 |
2024-10-10 |
Shandong Boan Biotechnology Co., Ltd. |
Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
EP4522204A1
(en)
|
2022-05-11 |
2025-03-19 |
Autolus Limited |
Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
WO2025250011A1
(en)
|
2024-05-29 |
2025-12-04 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Treatment for cancer
|
|
WO2025259108A1
(en)
|
2024-06-11 |
2025-12-18 |
Prinses Máxima Centrum Voor Kinderoncologie B.V. |
Brain organoid
|